U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Combination Products
  3. About Combination Products
  4. Combination Products Policy Council
  1. About Combination Products

Combination Products Policy Council

About Us

The Combination Products Policy Council provides a senior-level forum to establish combination product policy across the FDA and ensures that policy is implemented in a consistent manner throughout the Agency.

  • The Council is chaired by the Deputy Commissioner for Medical Products and Tobacco (OMPT) or his/her designee, comprised of the following members (see table below), and supported by an Executive Secretary. Council members include:

Combination Products Policy Council Representation

Center/Office Participants
Center for Biologics Evaluation and Research (CBER)
  • Center Director or designee
  • Center representative
Center for Drug Evaluation and Research (CDER)
  • Center Director or designee
  • Center representative
Center for Devices and Radiological Health (CDRH)
  • Center Director or designee
  • Center representative
Office of Combination Products
  • Office Director or designee
Office of Special Medical Programs
  • Office Director or designee
  • The Council will prospectively identify regulatory and scientific policy issues to address and function as a forum for developing guiding principles related to combination products, cross-labeled products, and medical product classification.
  • The Council will resolve disagreements among Centers, the Office of Combination Products (OCP), and/or sponsors on activities and policies related to medical product classification and the clearance/approval of combination products and cross-labeled products. The Council does not meet directly with sponsors.

For more information about the Council, please reach out to: combinationproductcouncil@fda.hhs.gov.

What’s New?

 

 

Back to Top